Download ThromboGenics 2-Year OASIS Study Results Published in

ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology,
Journal of the American Academy of Ophthalmology (AAO)
Leuven, 8 August 2016 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology
company developing novel medicines for diabetic eye diseases, today announces that the
results from its 2 Year OASIS Phase IIIb study with JETREA® (ocriplasmin) have been
published in the renowned AAO Journal Ophthalmology.
Ophthalmology reviewed the OASIS study which was a Phase IIIb randomized, sham
controlled, double masked study that followed up patients for 24 months post injection. The
study was designed to provide long term controlled efficacy and safety data for JETREA® in
patients being treated for symptomatic vitreomacular adhesion (sVMA). The study included
24 months follow up data, the longest period patients have been studied post treatment with
this novel medicine.
In its overall conclusion, Ophthalmology confirms ‘the OASIS trial demonstrates the longterm efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA
compared with previous phase 3 trials with no additional safety signals identified’.
The article ‘Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular
Adhesion Including Macular Hole (OASIS) Randomized Trial’ can be consulted online here.
Dr Patrik De Haes, CEO of ThromboGenics, said: “We are pleased that the positive
results from this Phase IIIb randomized, controlled trial have now been published in the
prestigious AAO Journal Ophthalmology. We are confident that the OASIS data will provide
very helpful guidance to the global retina community in their assessment of JETREA® as an
effective and safe treatment option for an important group of patients with symptomatic
VMA.”
The OASIS study results, including the sub-study read out, will be the subject of various
presentations delivered at upcoming US and global retina specialists educational meetings,
such as next week’s 34th Annual Scientific Meeting of the American Society of Retina
Specialists (ASRS) in San Francisco, and the Annual Meeting of the American Academy of
Ophthalmology (AAO) from the 15thto 18th October in Chicago.
Ends
For further information please contact:
ThromboGenics
Citigate Dewe Rogerson
Wouter Piepers, Global Head of Corporate
Communications & Investor Relations
Tel: +32 16 75 13 10 / +32 478 33 56 32
[email protected]
David Dible/ Sylvie Berrebi
Tel: +44 20 7282 1052
[email protected]
About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on developing innovative
treatments for diabetic eye disease.
ThromboGenics pioneered the new drug category of pharmacological vitreolysis with
JETREA® (ocriplasmin) which is approved for treatment of vitreomacular traction in 54
countries worldwide.
The company’s pipeline of disease modifying drug candidates (THR-409, THR-317, THR149, THR-687) targets all key segments of the diabetic eye disease market: diabetic
retinopathy (DR, NPDR, PDR) and/or diabetic macular edema (DME).
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available at
www.thrombogenics.com
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forwardlooking statements are based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company therefore cannot provide any
assurance that such forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement, whether as a result of new
information, future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual results to differ
materially from any forward-looking statement is contained in the Company’s Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of
securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics
may be offered or sold within the United States without registration under the U.S. Securities
Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance
with any applicable U.S. state securities laws.